Huh, maybe they will splain this concept to FDA. Nice. BTW, where have we heard the CAUSE discussion before...hint...RIGHT HERE. WOW, you mean running endless Amyloid Trials for the last 30+ years on taxpayers dime was a mistake??
“Unraveling the complex biological mechanisms that cause Alzheimer’s disease is critical for therapeutic development,” said NIH Director Francis S. Collins, M.D., Ph.D. “AMP AD 2.0 aims to add greater precision to the molecular maps developed in the first iteration of this program. This will identify biological targets and biomarkers to inform new therapeutic interventions for specific disease subtypes.”
I wonder if we get a grant from the NIH based on all the dot connecting that could possibly happen here. Take Missling’slittle panel discussion yesterday with NIH rare disease day followed up by this article. May be a few dots to connect that could lead to a few extra dollars in their pocket and maybe speed up the process a bit. It’s nice to have friends in high places.
Market Data 
Markets 
